Spruce Biosciences Inc
SPRB78.740USD
+1.970+2.57%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
44.37MMarket Cap
LossP/E TTM
More Details of Spruce Biosciences Inc Company
Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for neurological disorders with significant unmet medical need. The Company has acquired an exclusive worldwide license agreement for tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB). The TA-ERT is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) with modified human insulin-like growth factor 2 via an amino acid linker. TA-ERT is intended as an enzyme replacement therapy for the treatment of patients with MPS IIIB who lack rhNAGLU enzyme activity. The Company's pipeline also includes Tildacerfont and Cortibon for the treatment of Major Depressive Disorder, SPR202 for the treatment of Congenital Adrenal Hyperplasia and SPR204 for the treatment of Post-Bariatric Hypoglycemia.
Spruce Biosciences Inc Info
Ticker SymbolSPRB
Company nameSpruce Biosciences Inc
IPO dateOct 09, 2020
CEOSzwarcberg (Javier)
Number of employees21
Security typeOrdinary Share
Fiscal year-endOct 09
Address611 Gateway Boulevard, Suite 740
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone14156554168
Websitehttps://sprucebio.com/
Ticker SymbolSPRB
IPO dateOct 09, 2020
CEOSzwarcberg (Javier)
Company Executives of Spruce Biosciences Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Kirk Ways, M.D., Ph.D.
Dr. Kirk Ways, M.D., Ph.D.
Interim Chief Medical Officer, Director
Interim Chief Medical Officer, Director
--
--
Mr. Samir M. Gharib, CPA
Mr. Samir M. Gharib, CPA
President, Chief Financial Officer
President, Chief Financial Officer
--
--
Mr. Percival Barretto-Ko
Mr. Percival Barretto-Ko
Independent Director
Independent Director
--
--
Mr. Michael G. (Mike) Grey
Mr. Michael G. (Mike) Grey
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Javier Szwarcberg, M.D.
Dr. Javier Szwarcberg, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Camilla V. Simpson
Ms. Camilla V. Simpson
Independent Director
Independent Director
--
--
Mr. Daniel K. (Dan) Spiegelman
Mr. Daniel K. (Dan) Spiegelman
Independent Director
Independent Director
--
--
Dr. Tiba Aynechi, Ph.D.
Dr. Tiba Aynechi, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Kirk Ways, M.D., Ph.D.
Dr. Kirk Ways, M.D., Ph.D.
Interim Chief Medical Officer, Director
Interim Chief Medical Officer, Director
--
--
Mr. Samir M. Gharib, CPA
Mr. Samir M. Gharib, CPA
President, Chief Financial Officer
President, Chief Financial Officer
--
--
Mr. Percival Barretto-Ko
Mr. Percival Barretto-Ko
Independent Director
Independent Director
--
--
Mr. Michael G. (Mike) Grey
Mr. Michael G. (Mike) Grey
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Javier Szwarcberg, M.D.
Dr. Javier Szwarcberg, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Camilla V. Simpson
Ms. Camilla V. Simpson
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2025Q2
FY2025Q1
FY2024
FY2023
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Nov 27
Updated: Thu, Nov 27
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Ikarian Capital LLC
11.34%
Citadel Advisors LLC
10.24%
Squadron Capital Management LLC
6.54%
Boone (Peter David)
6.37%
Abingworth Management Limited
3.61%
Other
61.90%
Shareholders
Shareholders
Proportion
Ikarian Capital LLC
11.34%
Citadel Advisors LLC
10.24%
Squadron Capital Management LLC
6.54%
Boone (Peter David)
6.37%
Abingworth Management Limited
3.61%
Other
61.90%
Shareholder Types
Shareholders
Proportion
Hedge Fund
24.38%
Individual Investor
8.68%
Venture Capital
7.60%
Investment Advisor
6.57%
Investment Advisor/Hedge Fund
2.49%
Other
50.27%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
83
157.14K
27.94%
-358.28K
2025Q2
88
253.92K
45.09%
-361.84K
2025Q1
95
22.07M
52.76%
-20.96M
2024Q4
99
24.56M
59.47%
-18.72M
2024Q3
101
23.45M
56.77%
-19.98M
2024Q2
107
23.28M
56.39%
-18.72M
2024Q1
131
24.69M
59.95%
-15.12M
2023Q4
118
35.07M
86.32%
-2.09M
2023Q3
122
34.74M
85.52%
-5.50M
2023Q2
128
34.84M
85.77%
-7.44M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Ikarian Capital LLC
13.33K
2.37%
--
--
Jun 30, 2025
Armistice Capital LLC
28.92K
5.14%
--
--
Apr 01, 2025
HealthCap AB
39.70K
7.05%
--
--
Apr 01, 2025
RiverVest Venture Partners, LLC
15.58K
2.77%
-23.57K
-60.20%
Jan 07, 2025
Szwarcberg (Javier B M.D.)
6.23K
1.11%
--
--
Apr 01, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
Dimensional US Core Equity 1 ETF
0%
Avantis US Small Cap Equity ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
DFA Dimensional US Core Equity Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Spruce Biosciences Inc?
The top five shareholders of Spruce Biosciences Inc are:
Ikarian Capital LLC holds 13.33K shares, accounting for 2.37% of the total shares.
Armistice Capital LLC holds 28.92K shares, accounting for 5.14% of the total shares.
HealthCap AB holds 39.70K shares, accounting for 7.05% of the total shares.
RiverVest Venture Partners, LLC holds 15.58K shares, accounting for 2.77% of the total shares.
Szwarcberg (Javier B M.D.) holds 6.23K shares, accounting for 1.11% of the total shares.
Ikarian Capital LLC holds 13.33K shares, accounting for 2.37% of the total shares.
Armistice Capital LLC holds 28.92K shares, accounting for 5.14% of the total shares.
HealthCap AB holds 39.70K shares, accounting for 7.05% of the total shares.
RiverVest Venture Partners, LLC holds 15.58K shares, accounting for 2.77% of the total shares.
Szwarcberg (Javier B M.D.) holds 6.23K shares, accounting for 1.11% of the total shares.
What are the top three shareholder types of Spruce Biosciences Inc?
The top three shareholder types of Spruce Biosciences Inc are:
Ikarian Capital LLC
Citadel Advisors LLC
Squadron Capital Management LLC
Ikarian Capital LLC
Citadel Advisors LLC
Squadron Capital Management LLC
How many institutions hold shares of Spruce Biosciences Inc (SPRB)?
As of 2025Q3, 83 institutions hold shares of Spruce Biosciences Inc, with a combined market value of approximately 157.14K, accounting for 27.94% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -17.15%.
What is the biggest source of revenue for Spruce Biosciences Inc?
In FY2025Q2, the -- business generated the highest revenue for Spruce Biosciences Inc, amounting to -- and accounting for --% of total revenue.
